Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Increases By 231.8%

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 765,484 shares, a growth of 231.8% from the May 31st total of 230,679 shares. Based on an average trading volume of 346,077 shares, the short-interest ratio is currently 2.2 days. Approximately 4.9% of the shares of the company are sold short.

Cel-Sci Stock Performance

Shares of Cel-Sci stock traded down $0.03 on Monday, hitting $1.08. 333,083 shares of the company’s stock were exchanged, compared to its average volume of 255,776. Cel-Sci has a 1 year low of $0.89 and a 1 year high of $13.48. The company has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $3.68. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.54 and a current ratio of 0.60. The stock has a market capitalization of $18.88 million, a PE ratio of -0.11 and a beta of 0.54.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. US Bancorp DE bought a new position in shares of Cel-Sci during the 3rd quarter valued at approximately $80,000. HighTower Advisors LLC purchased a new stake in shares of Cel-Sci in the fourth quarter worth $53,000. HRT Financial LP bought a new stake in shares of Cel-Sci during the 4th quarter valued at $60,000. XTX Topco Ltd bought a new stake in shares of Cel-Sci during the 4th quarter valued at $66,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Cel-Sci during the 4th quarter valued at $81,000. 12.08% of the stock is owned by hedge funds and other institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.